Consistently, a retrospective case-control analysis of ovarian cancer patients enrolled in the ARIEL2 and ARIEL3 trials suggested an increased incidence of tMN among patients carrying pathogenic variants in genes involved in homologous recombination pathway (BRCA1, BRCA2, RAD51C and RAD51D) [24]. The gene discussed is RAD51D; the disease is therapy-related myeloid neoplasm.